^
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
ARX788
Sensitive: C3 – Early Trials
Ambrx Press Release - 1 week
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
FLOT
Sensitive: C3 – Early Trials
BMC Cancer - 1 week
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
HER-2 Negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
disitamab vedotin
Sensitive: A1 - Approval
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
DOF
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
TCF
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
CaT
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
HER-2 Negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
DP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
FLOT
Sensitive: A2 - Guideline
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
docetaxel
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
docetaxel + irinotecan
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
IP
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
NTRK3 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER2 inhibitor
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
oxaliplatin
Sensitive: A2 - Guideline
TMB-H
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
paclitaxel + capecitabine
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
FOLFOX
Sensitive: A2 - Guideline
No biomarker
Gastroesophageal Junction Adenocarcinoma
carboplatin + 5-fluorouracil + docetaxel
Sensitive: A2 - Guideline
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: B - Late Trials
FGFR2b overexpression + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
FPA-144
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
Immunotherapy
Sensitive: B - Late Trials
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
No biomarker
Gastroesophageal Junction Adenocarcinoma
avelumab
Sensitive: B - Late Trials
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: B - Late Trials
MET expression
Gastroesophageal Junction Adenocarcinoma
AMG 102
Resistant: B - Late Trials
MET amplification
Gastroesophageal Junction Adenocarcinoma
AMG 102
Resistant: B - Late Trials
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: B - Late Trials
DKK1 overexpression
Gastroesophageal Junction Adenocarcinoma
DKN-01
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
sintilimab
Sensitive: B - Late Trials
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab + ipilimumab
Sensitive: C1 - Off-label
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
durvalumab
Resistant: C1 - Off-label
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
paclitaxel
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
PRS-343
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
rivoceranib
Sensitive: C2 – Inclusion Criteria
HER-2 underexpression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
IMAB362
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
camrelizumab
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
rivoceranib + camrelizumab
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Her-VAXX
Sensitive: C2 – Inclusion Criteria
FGFR2b overexpression
Gastroesophageal Junction Adenocarcinoma
FPA-144
Sensitive: C2 – Inclusion Criteria
HER-2 overexpression + PTEN deletion
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Resistant: C3 – Early Trials
FGFR2b expression
Gastroesophageal Junction Adenocarcinoma
FPA-144
Sensitive: C3 – Early Trials
HER-2 expression + TMB-H
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: C3 – Early Trials